Triple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is relentless progressive parenchymal disease (1), and median survival is 2–3 years (2). Natural course of IPF patients is variable from stable disease, partly reversible, progressive deterioration to acute exacerbation (AE). IPF patients show significant decline of lung function especially both forced vital capacity (FVC) and diffusion capacity of the lungs for carbon monoxide (DLco) (3).